(Q37072039)

18 August 2017

Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies (English)

1 reference

18 August 2017

F Lamoth

1

0 references

Chantal Csajka

object named as

C Csajka

3

0 references

Thierry Calandra

object named as

T Calandra

5

0 references

Thierry Buclin

object named as

T Buclin

2

0 references

author name string

A Pascual

4

1 reference

18 August 2017

O Marchetti

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

Antimicrobial Agents and Chemotherapy

18 August 2017

1 reference

18 August 2017

53

1 reference

18 August 2017

2

1 reference

18 August 2017

785-787

1 reference

Continuous infusion of beta-lactams.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Prospective determination of plasma imipenem concentrations in critically ill children.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Pharmacodynamics of cefepime in patients with Gram-negative infections

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Comparative pharmacokinetics of the carbapenems: clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Increased aminoglycoside dosage requirements in hematologic malignancy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Tissue distribution of imipenem in critically ill patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2630622

Prevention of resistance: a goal for dose selection for antimicrobial agents

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19047655

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19047655

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The pharmacodynamics of beta-lactams

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19047655

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00891-08

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19047655

1 reference